Sign In
Buy VERU
$2.25
-0.100 (-4.26%)
At Close: Jun 03, 2026
Veru to Present at the GLP-1 Based Therapeutics Summit
08:30am, Thursday, 02'nd May 2024
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
08:30am, Wednesday, 01'st May 2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Tuesday, 30'th Apr 2024
Veru Inc. (VERU) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VERU's 50-day simple moving average crossed above its 200-da
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
08:30am, Tuesday, 30'th Apr 2024
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 --
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
08:30am, Thursday, 25'th Apr 2024
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high qualit
What Makes Veru (VERU) a New Buy Stock
01:01pm, Wednesday, 17'th Apr 2024
Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Veru Reschedules Annual Meeting of Shareholders
04:05pm, Friday, 22'nd Mar 2024
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings--
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
08:00am, Tuesday, 12'th Mar 2024
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality we
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
07:15pm, Tuesday, 27'th Feb 2024
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quali
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
08:30am, Tuesday, 20'th Feb 2024
MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality w
The 3 Best Penny Stocks to Buy in February 2024
07:49am, Thursday, 15'th Feb 2024
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of co
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
10:36am, Tuesday, 13'th Feb 2024
The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
01:36pm, Thursday, 08'th Feb 2024
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
Veru Reports Fiscal 2024 First Quarter Financial Highlights
06:30am, Thursday, 08'th Feb 2024
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone—
FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone
